Skip to main content
Themis Medicare Ltd. logo

Themis Medicare Ltd. — Investor Relations & Filings

Ticker · THEMISMED ISIN · INE083B01024 LEI · 335800LHRDVIKH69AF42 BSE.NS Manufacturing
Open in API
Filings indexed 707 across all filing types
Latest filing 2025-01-02 Regulatory Filings
Country IN India
Listing BSE.NS THEMISMED

About Themis Medicare Ltd.

https://www.themismedicare.com/

Themis Medicare Ltd. is a research-driven pharmaceutical organization specializing in the development, manufacture, and marketing of a diverse range of therapeutic products. The company focuses on high-value segments including pain management, anesthesia, critical care, anti-infectives, and oncology. Its core competencies lie in the production of Active Pharmaceutical Ingredients (APIs) and complex finished dosage formulations, particularly injectables. Themis Medicare maintains a strong emphasis on Research and Development, operating state-of-the-art facilities that adhere to international quality standards such as WHO-GMP. Through strategic partnerships and a robust supply chain, the company serves both domestic and international markets, providing specialized medical solutions for hospital-based care and chronic disease management. Its portfolio includes proprietary delivery systems and differentiated generic products designed to improve patient outcomes.

Recent filings

Filing Released Lang Actions
General Updates
Regulatory Filings Classification · 95% confidence The document is a short formal letter addressed to stock exchanges informing about a change in the name of the Registrar and Share Transfer Agent (RTA) of the company. It does not contain financial data, audit information, or any report content. It is an announcement of a corporate administrative change related to share transfer agents. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like management changes or capital changes.
2025-01-02 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) notifying the closure of the trading window in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. It mentions the trading window closure period related to the upcoming financial results for the quarter ending 31st December 2024. The document does not contain any financial data, results, or detailed report content. It is an announcement related to insider trading compliance and timing of trading restrictions, not a financial report or earnings release. The document length is short (1956 characters), and it serves as an intimation or regulatory announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and regulatory notices that do not fit other specific categories.
2024-12-26 English
Delay/default in the payment of fines/penalties/dues etc. to authority
Regulatory Filings Classification · 95% confidence The document is a short notice informing about the receipt of a tax demand notice from the Income Tax Department for a specific assessment year (2018-19). It mentions the company's intention to take legal steps and is addressed to stock exchanges as an intimation under SEBI Listing Regulations. There are no financial statements, detailed financial data, or report attachments. The document serves as a regulatory announcement about a legal/tax matter rather than a full report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement.
2024-11-19 English
Spurt in Volume
Merger & Acquisition Classification · 95% confidence The document is a detailed disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, concerning the outcome of a Board meeting held on November 18, 2024. It includes information about the termination of a previous agreement and the approval of a scheme of amalgamation between Themis Medicare Limited and Gujarat Themis Biosyn Limited. The document contains detailed annexures with financial data, rationale for the amalgamation, shareholding patterns pre- and post-amalgamation, and regulatory compliance references. It is not a full annual or interim financial report, nor is it a simple announcement or certification. The content focuses on corporate restructuring and merger-related disclosures, which aligns with filings related to merger and acquisition activities. Therefore, the appropriate classification is Merger & Acquisition (MA). The document length (12,253 characters) and detailed content support this classification with high confidence.
2024-11-19 English
Press Release
M&A Activity Classification · 95% confidence The document is a press release announcing the approval of a Scheme of Amalgamation between Gujarat Themis Biosyn Limited and Themis Medicare Limited. It includes details about the share exchange ratio, approvals required, and advisors involved. The document is relatively short (4310 characters) and is clearly labeled as a press release. It does not contain detailed financial statements or comprehensive merger documentation such as a merger proxy statement or tender offer forms. It is an announcement related to a merger activity but not the formal merger filing itself. According to the filing definitions, announcements related to merger proposals or takeover bids fall under 'M&A Activity' (Code: TAR). Therefore, this document should be classified as M&A Activity (TAR).
2024-11-18 English
Outcome of Board Meeting
Regulatory Filings Classification · 95% confidence The document is a formal disclosure made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, which pertains to the outcome of a Board meeting. The content includes the termination of a previous agreement and the approval of a draft Scheme of Amalgamation between two companies. It details the rationale, financials, and shareholding changes related to the amalgamation. There is no presentation of financial statements or detailed financial performance data typical of Annual Reports or Interim Reports. Instead, it is an announcement of corporate actions and decisions made by the Board. The document is not a proxy solicitation, voting results, or remuneration report. It is also not a transcript, earnings release, or legal proceeding update. The primary focus is on corporate restructuring and merger-related disclosures, which aligns with announcements related to M&A activity. However, since this is a disclosure of the Board meeting outcome and details of the scheme, and not the actual merger filing forms (like DEFM14A or SC TO-*), it fits best under Regulatory Filings (RNS) as a general regulatory announcement about corporate actions under SEBI regulations. The document length and detail confirm it is not a brief announcement but a detailed regulatory filing. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2024-11-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.